Health insurance company Cigna (NYSE: CI) announced better-than-expected revenue in Q1 CY2026, with sales up 4.7% year on year to $68.52 billion. Its non-GAAP profit of $7.79 per share was 2.4% above analysts’ consensus estimates.

Is now the time to buy CI? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Cigna’s first quarter results reflected momentum in its core health services and specialty pharmacy businesses, as management highlighted strong demand for specialty drugs and continued investment in technology. CEO David Cordani cited improvements in operational efficiency and customer-focused initiatives, such as streamlining prior authorizations and leveraging AI to enhance patient engagement. Specialty and Care Services, in particular, saw robust adoption of biosimilars and specialty generics, which management pointed to as key factors supporting margin stability and cost management. CFO Ann Dennison noted that lower flu volumes and weather-related care deferrals also contributed to favorable medical cost trends for the quarter.

Looking forward, Cigna’s updated guidance is underpinned by a sharpened focus on core health platforms, the roll-out of its rebate-free pharmacy benefits model called Signature, and continued investment in AI-driven personalization. Incoming CEO Brian Evanko emphasized the importance of scaling specialty services, expanding digital tools, and advancing affordability for both employers and patients. Management expects ongoing portfolio reshaping, including the exit from the individual exchange business and a strategic review of eviCore, to enable greater focus on high-growth segments. Evanko stated, “We are well positioned to lead the next era of consumer-focused and AI-enabled health services, emphasizing clinically complex patients and driving value for all stakeholders.”

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to growth in specialty pharmacy, operational streamlining, and portfolio decisions aimed at focusing on higher-value segments.

• Specialty pharmacy momentum: Cigna saw continued strength in its Specialty and Care Services segment, with management attributing this to growing demand for specialty medications, increased biosimilar adoption, and the integration of recent acquisitions like Shields Health Solutions and CarepathRx. These factors contributed to higher adoption rates and improved patient outcomes.
• AI and analytics integration: The company expanded its use of advanced analytics and artificial intelligence to personalize care, predict high-cost claimants, and streamline administrative tasks. Management noted that these efforts have led to measurable reductions in unnecessary emergency room visits and improved customer satisfaction, as evidenced by a 20-25% drop in call volumes among digitally engaged members.
• Portfolio reshaping: Cigna announced plans to exit the individual exchange health insurance market by the end of this year, citing limited scalability and a desire to intensify focus on core growth platforms. Additionally, it launched a strategic review of alternatives for its prior authorization and utilization management unit, eviCore, as industry standards evolve toward automation and transparency.
• Pharmacy benefit model transition: The forthcoming Signature model, a rebate-free pharmacy service, is designed to guarantee patients the lowest out-of-pocket cost on branded drugs. Management highlighted positive early feedback from clients and expects at least half of its pharmacy benefit services members to transition to this model by 2028, improving affordability and transparency for employers and patients.
• Cost management and care trends: The quarter benefited from lower-than-expected flu volumes and weather-driven care deferrals, which supported margin stability in the health insurance business. Management also pointed to a higher mix of bronze plan members, affecting medical cost ratios but not altering the full-year outlook.

Drivers of Future Performance

Cigna’s outlook centers on scaling specialty services, advancing digital and AI investments, and optimizing its business mix through ongoing portfolio actions.

• Specialty segment expansion: Management expects sustained mid- to high-single-digit growth in specialty pharmacy, supported by rising biosimilar penetration, expanded hospital partnerships, and increased investment in infusion and specialty generics. These trends are anticipated to drive margin improvement and market differentiation.
• Signature model rollout: The transition to the rebate-free Signature pharmacy benefit is projected to address affordability challenges and regulatory pressures facing employers and plan sponsors. Early client feedback has been positive, and management aims for broad adoption by 2028, expecting this model to enhance transparency and predictability in drug spending.
• Portfolio focus and AI adoption: The exit from the individual exchange market and the eviCore strategic review are intended to concentrate resources on core growth platforms. Investments in AI and analytics are expected to further reduce administrative burden, personalize care, and support proactive health interventions, though management acknowledged that persistent medical cost trends and regulatory changes remain risks.

Catalysts in Upcoming Quarters

In the coming quarters, our analyst team will be tracking (1) the pace of client transitions to the Signature pharmacy benefit model and feedback on its impact, (2) progress on portfolio reshaping, specifically any developments regarding the eviCore strategic review and exit from the individual exchange market, and (3) ongoing adoption rates and profitability within the specialty pharmacy segment, especially biosimilars and partnerships with hospitals. We will also pay close attention to the impact of AI-driven tools on cost trends and customer retention.

Cigna currently trades at $287.51, down from $292.32 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

High Quality Stocks for All Market Conditions

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.